pioglitazone has been researched along with Colorectal Cancer in 9 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-Ay obesity and diabetes model mice, and tried to clarify mechanisms by which the PPARγ ligand inhibits ACF development." | 7.78 | Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice. ( Fujii, G; Komiya, M; Mutoh, M; Nakano, K; Takahashi, M; Takasu, S; Teraoka, N; Ueno, T; Wakabayashi, K; Yamamoto, M; Yanaka, A, 2012) |
| "CAP, PGZ, and combination treatment nano-formulations were prepared by triblock (TB) (PCL-PEG-PCL) biodegradable copolymers to enhance drugs' bioavailability as anti-cancer agents." | 5.91 | Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers. ( Fathi-Azarbayjani, A; Kheradmand, F; Pouya, FD; Rasmi, Y; Salehi, R, 2023) |
| " In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-Ay obesity and diabetes model mice, and tried to clarify mechanisms by which the PPARγ ligand inhibits ACF development." | 3.78 | Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice. ( Fujii, G; Komiya, M; Mutoh, M; Nakano, K; Takahashi, M; Takasu, S; Teraoka, N; Ueno, T; Wakabayashi, K; Yamamoto, M; Yanaka, A, 2012) |
| "Considering the role of PPARγ in colorectal cancer (CRC) as a tumor suppressor, the GEO database was used to identify candidate genes that affect the activation of PPARγ protein in CRC cell lines." | 2.82 | Identification of a novel interplaying loop of PPARγ and respective lncRNAs are involved in colorectal cancer progress. ( Esmaeili, M; Ghaedi, K; Hajipour, M; Hasehmi, M; Hushmandi, K; Mahdevar, M; Mirzaei, S; Mokhtari, K; Nasr-Esfahani, MH; Peymani, M, 2022) |
| "Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined." | 2.50 | Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014) |
| "CAP, PGZ, and combination treatment nano-formulations were prepared by triblock (TB) (PCL-PEG-PCL) biodegradable copolymers to enhance drugs' bioavailability as anti-cancer agents." | 1.91 | Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers. ( Fathi-Azarbayjani, A; Kheradmand, F; Pouya, FD; Rasmi, Y; Salehi, R, 2023) |
| "Pioglitazone was chosen as agonist of PPAR-gamma and GW9662 used as a specific complete antagonist of PPAR-gamma." | 1.35 | [Role of peroxisome proliferators-activated receptor-gamma in the chemical prevention therapy of sulindac for precancerous lesions of rats]. ( Han, YJ; Jin, Z; Li, CF; Li, J; Lv, YM; Zhang, YP, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Hajipour, M | 1 |
| Mokhtari, K | 1 |
| Mahdevar, M | 1 |
| Esmaeili, M | 1 |
| Peymani, M | 1 |
| Nasr-Esfahani, MH | 1 |
| Mirzaei, S | 1 |
| Hasehmi, M | 1 |
| Hushmandi, K | 1 |
| Ghaedi, K | 1 |
| Jia, X | 1 |
| Qian, J | 1 |
| Chen, H | 2 |
| Liu, Q | 2 |
| Hussain, S | 1 |
| Jin, J | 2 |
| Shi, J | 2 |
| Hou, Y | 2 |
| Xu, L | 1 |
| Che, S | 1 |
| Pouya, FD | 1 |
| Salehi, R | 1 |
| Rasmi, Y | 1 |
| Kheradmand, F | 1 |
| Fathi-Azarbayjani, A | 1 |
| Herrigel, DJ | 1 |
| Moss, RA | 1 |
| Zhang, YP | 1 |
| Lv, YM | 1 |
| Li, J | 1 |
| Han, YJ | 1 |
| Jin, Z | 1 |
| Li, CF | 1 |
| Ueno, T | 1 |
| Teraoka, N | 1 |
| Takasu, S | 1 |
| Nakano, K | 1 |
| Takahashi, M | 1 |
| Yamamoto, M | 1 |
| Fujii, G | 1 |
| Komiya, M | 1 |
| Yanaka, A | 1 |
| Wakabayashi, K | 1 |
| Mutoh, M | 1 |
| Lee, CJ | 1 |
| Han, JS | 1 |
| Seo, CY | 1 |
| Park, TH | 1 |
| Kwon, HC | 1 |
| Jeong, JS | 1 |
| Kim, IH | 1 |
| Yun, J | 1 |
| Bae, YS | 1 |
| Kwak, JY | 1 |
| Park, JI | 1 |
| Richard, CL | 1 |
| Blay, J | 1 |
2 reviews available for pioglitazone and Colorectal Cancer
| Article | Year |
|---|---|
Identification of a novel interplaying loop of PPARγ and respective lncRNAs are involved in colorectal cancer progress.
Topics: Colonic Neoplasms; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Ligands; Pi | 2022 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp | 2014 |
7 other studies available for pioglitazone and Colorectal Cancer
| Article | Year |
|---|---|
PPARγ agonist pioglitazone enhances colorectal cancer immunotherapy by inducing PD-L1 autophagic degradation.
Topics: B7-H1 Antigen; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Humans; Immunotherapy; Pioglitazone | 2023 |
PPARγ agonist inhibits c-Myc-mediated colorectal cancer tumor immune escape.
Topics: Colorectal Neoplasms; Gene Expression Regulation; Humans; Pioglitazone; PPAR gamma; Proto-Oncogene P | 2023 |
Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Drug Therapy, Combination; Human Umbilica | 2023 |
[Role of peroxisome proliferators-activated receptor-gamma in the chemical prevention therapy of sulindac for precancerous lesions of rats].
Topics: 1,2-Dimethylhydrazine; Anilides; Animals; Colorectal Neoplasms; Male; Pioglitazone; PPAR gamma; Prec | 2009 |
Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice.
Topics: Aberrant Crypt Foci; Adipokines; Animals; Azoxymethane; Biomarkers; Carcinogens; Colorectal Neoplasm | 2012 |
Pioglitazone, a synthetic ligand for PPARgamma, induces apoptosis in RB-deficient human colorectal cancer cells.
Topics: Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Cyclooxygenase 2; | 2006 |
Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Colorectal Neoplasms; Dose-Response Relation | 2007 |